Evaluation of a prototype real-time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening;Evaluación de un sistema de PCR a tiempo real (cobas 4800) para la detección separada de los genotipos 16 y 18 y otros genotipos de alto riesgo del virus del papiloma humano en la prevención del cáncer cervical

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue 6, 2011, Pages 411-414

  Mateos, María Luisa ^a   Chacón De Antonio, Jesús ^a   Rodríguez Domínguez, Mario ^a   Sanz, Itziar ^a   Rubio, María Dolores ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Cervical cancer; Cervical cancer screening; HPV genotypes; Human papilloma virus

Indexed keywords

ARTICLE; CANCER SCREENING; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HYBRID CAPTURE 2; INTERMETHOD COMPARISON; LINEAR ARRAY HPV TEST; NONHUMAN; PAPILLOMA VIRUS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; REAL-TIME POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 79959363514     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2011.01.007     Document Type: Article

References (18)

1. Muñoz N, Castellsague X, Berrington de González A, Gissman L. HPV in the etiology of human cancer. Vaccine. 2006; 24 Suppl 3:S3/1-10. Epub 2006 Jun 23. Review.
2. Muñoz N. Human papillomavirus and cancer: the epidemiological evicence. J Clin Virol. 2000;19:1-5.
3. Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342:792-800. (Pubitemid 30151924)
4. Genital HPV Infection. CDC Fact Sheet. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Ga. Disponible en http://www.cdc.gov/std/HPV/STDFactHPV.htm/cancer. Agosto 2007.
5. Maynard MH, Duarte Franco E, Rodríguez I, Stephen DW, Hanley J, Ferenczy A, et al., for the Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-88. (Pubitemid 47598400)
6. Cortés J, Martinón-Torres F, Ramón y Cajal JM, Gil A, Velasco J, Abizanda M, et al. Prevención primaria y secundaria de los cánceres de cuello de útero y vulva: recomendaciones para la práctica clínica. Prog Obstet Ginecol. 2010;53 Suppl 1:1-19.
7. Clavel C, Coucherousset J, Lorenzato M, Caudroy S, Nou JM, Nazeyrollas P, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high grade cervical lesions. Br J Cancer. 2004;90:1803-8. (Pubitemid 38725657)
8. Wrigth TC, Schiffman M, Solomon D, Cox T, García F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-9.
9. Mateos Lindemann ML, Sánchez Calvo JM, Chacón de Antonio, Sanz I, Díaz E, Rubio MD, de la Morena ML. Prevalence and distribution of high-risk genotypes of HPV in women with severe cervical lesions in Madrid, Spain: importance of detecting genotype 16 and other high-risk genotypes. SAGE-Hindawi Access to Research. Advances in Preventive Medicine. 2011, 269468: 4. doi:10. 4061/2011/269468.
10. Safaeian M. Detection of precancerous cervical lesions is differential by human papilloma type. Cancer Res. 2009;69:3262-6.
11. Wright T, Massad S, Dunton C, Spitzer M, Wilkinson E, Solomon D, et al. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346-55. Review.
12. Chacón de Antonio J, Fernández-Olmos A, Mercadillo M, Mateos Lindemann ML, Baquero Mochales F. Detection of high-risk human papillomavirus by two molecular techniques: Hybrid capture and linear array. J Virol Meth. 2008;149:163-6.
13. Castle P, Sadorra M, Lau T, Aldrich C, García F, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic Human Papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV 18 genotyping. J Clin Microbiol. 2009;47:3344-7.
14. Sargent A, Bailey A, Turner A, Almonte M, Gilham C, Baysson H, et al. Optimal threshold for a positive Hybrid Capture 2 Test for detection of human papillomavirus: data from the ARTISTIC Trial. J Clin Microbiol. 2010;48: 554-8.
15. Meijer CJ, Berkof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516-20.
16. Intenational Agency for Research on Cancer (IARC), World Health Organization. IARC handbooks of cancer prevention: cervix cancer screening vol10. IARC Press: Lyon, France; 2005.
17. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-9. (Pubitemid 41417924)
18. De Sanjosé S, Quint W, Geraets D, Klaustermeir JE, Lloveras B, Tous S, et al. Human papillomavirus genotype atribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. The Lancet Oncology. 2010; 101016/S1470-2045(10)70230-8.